Skip to main content
. 2014 Mar 10;106(4):dju013. doi: 10.1093/jnci/dju013

Figure 3.

Figure 3.

Kaplan–Meier survival curves of castration-resistant prostate cancer (CRPC) patients with low (<25th percentile; left image) and high (≥25th percentile; right image) bone marker levels. Y-axis represents overall survival probability. Patients with the highest levels of bone biomarkers not only have a very poor prognosis (hazard ratio [HR] = 4.3; 95% confidence interval [CI] = 2.41 to 7.65; P < .001) but have a statistically significant survival benefit from atrasentan (HR = 0.33; 95% CI = 0.15 to 0.71; P interaction = .005). Patients whose bone biomarkers were not in the upper 25th percentile did not benefit from atrasentan therapy, with a median survival time of approximately 19.5 months in both arms (P = .83). P values were calculated using the Wald test and are two-sided.